Catalent Enters Agreement to Sell Its U.S. Commercial Packaging Operations

Catalent Enters Agreement to Sell Its U.S. Commercial Packaging Operations

SOMERSET, NJ –May 30, 2012 — Catalent Pharma Solutions recently signed a definitive agreement to sell its U.S. commercial packaging operations based in Philadelphia, PA and Woodstock, IL to a company affiliated with Frazier Healthcare. The transaction is subject to certain closing conditions and is expected to close in the next few months.

The transaction does not involve Catalent's Clinical Supply Services operations in Philadelphia, or the Blow-Fill-Seal business in Woodstock.  It also does not involve any commercial packaging activity that Catalent conducts outside North America.

Catalent's decision to sell its U.S. commercial packaging operations is based on the company's business strategy to focus on growing its world leading businesses in development solutions and advanced delivery technologies, clinical trial supplies, advanced blow/fill/seal aseptic delivery technology for respiratory, ophthalmic and other products, as well as offering integrated solutions for the development and supply of injectable biologics and complex pharmaceutical products.

Frazier Healthcare was founded in 1991 to invest exclusively in healthcare, and is a leading provider of growth equity and venture capital to high growth and emerging healthcare companies.

About Catalent
From drug and biologic development services to delivery technologies to supply solutions, Catalent Pharma Solutions has the deepest expertise, the broadest offerings and the most unique technologies in the industry. With over 75 years of experience, Catalent helps customers get more molecules to market faster, enhance product performance, and provide superior, reliable manufacturing and packaging solutions. Catalent employs approximately 9,400 people at 29 facilities worldwide and in fiscal year 2011 generated more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, NJ.
 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

WCG is continuing its buyout run after acquiring clinical trial solutions firm Trifecta Clinical.

London-based uMed has raised nearly $4.8 million from U.K. and U.S. VCs to help healthcare providers participate in more clinical studies.

Amgen has teamed up with cloud-based trial solutions firm Reify Health to help boost patients into its drug studies.